bioAffinity Technologies' CyPath® Lung Test Sales Surge 146% in Q1

Got story updates? Submit your updates here. ›

bioAffinity Technologies, a San Antonio-based medical technology company, reported a 146% year-over-year increase in unit sales for its CyPath® Lung test during the first quarter of 2026. The CyPath® Lung test is a non-invasive, early-stage lung cancer screening tool that uses a patient's cells to detect the presence of lung cancer.

Why it matters

Early detection is critical for improving lung cancer survival rates, and the CyPath® Lung test provides a convenient, affordable option for screening high-risk individuals. The surge in sales suggests growing adoption of the test, which could lead to more lives saved through earlier diagnosis.

The details

The CyPath® Lung test collects cells from a patient's sputum sample and analyzes them for biomarkers associated with lung cancer. This allows for the detection of lung cancer in its earliest stages, when treatment is most effective. The test is designed to complement traditional imaging techniques like CT scans, providing an additional tool for comprehensive lung cancer screening.

• bioAffinity Technologies reported the Q1 2026 sales figures on April 1, 2026.

What’s next

bioAffinity Technologies plans to continue expanding access to the CyPath® Lung test through partnerships with healthcare providers and insurers, with the goal of making early lung cancer screening more widely available.